S&P Futures
3,434.50-17.25(-0.50%)Dow Futures
28,051.00-138.00(-0.49%)Nasdaq Futures
11,620.00-43.50(-0.37%)
Aytu BioScience, Inc. (AYTU)
Chart Events
Performance Outlook
| Previous Close | 1.0100 |
| Open | 1.0000 |
| Bid | 1.0000 x 1100 |
| Ask | 1.0100 x 4000 |
| Day's Range | 0.9850 - 1.0200 |
| 52 Week Range | 0.3400 - 2.9900 |
| Volume | 1,432,635 |
| Avg. Volume | 3,644,695 |
| Market Cap | 124.604M |
| Beta (5Y Monthly) | 0.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3010 |
| Earnings Date | Nov 12, 2020 - Nov 16, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.63 |
- Benzinga
Recap: Aytu BioScience Q4 Earnings
Shares of Aytu BioScience (NASDAQ:AYTU) fell 6.77% after the company reported Q4 results.Quarterly Results Earnings per share rose 98.46% over the past year to ($0.02), which beat the estimate of ($0.03).Revenue of $14,861,000 rose by 766.03% from the same period last year, which beat the estimate of $11,240,000.Looking Ahead Aytu BioScience hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.How To Listen To The Conference Call Date: Oct 06, 2020View more earnings on AYTUTime: 04:30 PMET Webcast URL: https://www.webcaster4.com/Webcast/Page/2142/37506Price Action Company's 52-week high was at $2.99Company's 52-week low was at $0.34Price action over last quarter: down 14.42%Company Profile Aytu BioScience Inc is a specialty pharmaceutical company commercializing novel products addressing patient needs. The company markets a portfolio of prescription products addressing large therapeutic markets. The primary care portfolio includes Natesto, the only FDA-approved nasal formulation of testosterone, ZolpiMist, the only FDA-approved oral spray prescription sleep aid, and Tuzistra XR, the only FDA-approved 12-hour codeine-based antitussive syrup. The pediatric portfolio includes AcipHex Sprinkle, Cefaclor, Karbinal ER, and Poly-Vi-Flor and Tri-Vi-Flor.See more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * Earnings Scheduled For October 6, 2020 * Preview: Aytu BioScience's Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- ACCESSWIRE
Aytu BioScience Announces Fiscal Q4 2020 Net Revenue of $14.9 Million, an Increase of 82% Sequentially, and 766% Year-Over-Year
Company's highest revenue quarter to date is more than 2X its entire fiscal 2019 revenueENGLEWOOD, CO / ACCESSWIRE / October 6, 2020 / Aytu BioScience, Inc.
- Benzinga
Preview: Aytu BioScience's Earnings
Aytu BioScience (NASDAQ: AYTU) releases its next round of earnings this Tuesday, October 06. Get the latest predictions in Benzinga's essential guide to the company's Q4 earnings report.Earnings and Revenue Sell-side analysts are expecting Aytu BioScience's loss per share to be near $0.03 on sales of $11.24 million. Aytu BioScience's loss in the same period a year ago was $1.3 per share. Quarterly sales came in at $1.72 million. The analyst consensus estimate would represent a 97.69% increase in the company's earnings per share. In comparison to analyst estimates in the past, here's how the company's reported EPS stacks up:Quarter Q3 2020 Q2 2020 Q1 2019 Q4 2019 EPS Estimate -0.22 -0.24 -0.30 -2.15 EPS Actual -0.15 -0.31 -0.32 -1.30 Revenue Estimate 6.40 M 2.74 M 2.01 M 17.04 M Revenue Actual 8.16 M 3.17 M 1.44 M 1.72 M Stock Performance Over the last 52-week period, shares of Aytu BioScience are up 26.6%.View more earnings on AYTUDon't be surprised to see the stock move on comments made during its conference call. Aytu BioScience is scheduled to hold the call at 16:30:00 ET and can be accessed here: https://www.webcaster4.com/Webcast/Page/2142/37506See more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * Earnings Scheduled For September 24, 2020 * Aytu BioScience's Earnings Outlook(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
